Through the rights issue, the Company initially raises approximately SEK 19.4 million, before issue costs. Upon full utilisation of the issued warrants, the Company may receive an additional maximum of approximately SEK 20.8 million, before issue costs. The Company also issues a bond of SEK 3.7 million.

SensoDetect Aktiebolag is a Med Tech AI company listed on Spotlight Stock Market. The company offers products for diagnostics, medication and health within ADHD, schizophrenia, autism assessments, drug effect measurement and hearing screening, reducing the financial impact on the healthcare system and providing faster and safer results for patients and relatives.

For more information, see SensoDetect’s press release here.

Moll Wendén has been legal advisor and Mangold Fondkommission AB has been financial advisor to SensoDetect Aktiebolag in connection with the rights issue and the issuance bond.

Moll Wendén’s team has mainly consisted of Henric Stråth (responsible partner), Alexander Blom Vigsø and Eira Sjösvärd.